This company launched the first new therapy for Hodgkin lymphoma in many years using an all-new biotech platform of “armed antibodies.” By combining the targeting ability of antibodies (used by our own immune systems to take out invaders) with powerful chemotherapy drugs, one of our companies made history.
But I don't love this company just for creating a new cure for a cancer I once had. It just has so much going for it for a long-term investor.
It’s much more than a one-hit wonder. It has something that I love when I look for a biotechnology company in which to invest. Not only does it have a breakthrough platform technology, it also has a broad pipeline of new drugs in development with the promise of delivering growing revenues in the years ahead.
↧